Opaleye Management Inc. 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Opaleye Management Inc. disclosed 43 US equity positions worth $707.3m in its Q3 2025 13F filing. The largest position was HROW at 26.6% of the reported book, followed by ETON and LQDA. Against the Q2 2025 filing, it opened 11 new positions, added to 9 and reduced 11 among the top 43 holdings.
What did Opaleye Management Inc. own in Q3 2025? Top 43 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | HROW HARROW HEALTH INC | 26.6% | $188.1m | 3,905,000 | 0% | held | |
| 2 | ETON ETON PHARMACEUTICALS INC | 8.8% | $62.1m | 2,860,000 | 0% | held | |
| 3 | LQDA LIQUIDIA CORPORATION | Healthcare | 8.4% | $59.5m | 2,615,000 | 6% | added |
| 4 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 6.6% | $46.6m | 461,700 | -3% | reduced |
| 5 | IMNM IMMUNOME INC | Healthcare | 5.3% | $37.3m | 3,185,000 | -10% | reduced |
| 6 | SANUWAVE HEALTH INC | 5.2% | $36.7m | 980,000 | 0% | held | |
| 7 | CDXS CODEXIS INC | Healthcare | 4.4% | $31.2m | 12,795,000 | 2% | added |
| 8 | TGTX TG THERAPEUTICS INC | Healthcare | 2.7% | $19.3m | 535,000 | 0% | held |
| 9 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.6% | $18.6m | 1,595,000 | 0% | held |
| 10 | CGON CG ONCOLOGY INC | Healthcare | 2.3% | $16.5m | 410,000 | 54% | added |
| 11 | STOK STOKE THERAPEUTICS INC | Healthcare | 2.3% | $16.0m | 682,017 | 21% | added |
| 12 | APGE APOGEE THERAPEUTICS INC | Healthcare | 2.0% | $14.4m | 363,257 | – | new |
| 13 | ALKS ALKERMES PLC | Healthcare | 1.9% | $13.5m | 450,000 | – | new |
| 14 | IRON DISC MEDICINE INC | Healthcare | 1.8% | $12.8m | 193,773 | 4% | added |
| 15 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.6% | $11.3m | 585,000 | 17% | added |
| 16 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 1.5% | $10.6m | 3,720,867 | -9% | reduced |
| 17 | XOMA CORP DEL | 1.4% | $9.8m | 255,087 | 0% | held | |
| 18 | RZLT REZOLUTE INC | 1.2% | $8.5m | 903,442 | 0% | held | |
| 19 | ARVN ARVINAS INC | Healthcare | 1.2% | $8.4m | 987,818 | -41% | reduced |
| 20 | EWTX EDGEWISE THERAPEUTICS INC | 1.1% | $8.1m | 500,000 | 2% | added | |
| 21 | ANNX ANNEXON INC | Healthcare | 1.1% | $7.9m | 2,600,000 | – | new |
| 22 | GOSS GOSSAMER BIO INC | Healthcare | 1.0% | $7.2m | 2,725,000 | -23% | reduced |
| 23 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.0% | $7.0m | 105,000 | 0% | held |
| 24 | DERM JOURNEY MEDICAL CORP | 1.0% | $6.9m | 971,064 | 922% | added | |
| 25 | SOL GEL TECHNOLOGIES | 0.8% | $6.0m | 204,835 | – | new | |
| 26 | PLX PROTALIX BIOTHERAPEUTICS INC | Healthcare | 0.8% | $5.7m | 2,580,556 | – | new |
| 27 | TMCI TREACE MEDICAL CONCEPTS INC | Healthcare | 0.7% | $4.7m | 702,245 | – | new |
| 28 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.7% | $4.7m | 100,000 | -5% | reduced |
| 29 | KARYOPHARM THERAPEUTICS INC | 0.7% | $4.6m | 6,000,000 | 0% | held | |
| 30 | MBX MBX BIOSCIENCES INC | Healthcare | 0.6% | $4.4m | 253,000 | 6% | added |
| 31 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.5% | $3.6m | 390,000 | 0% | held |
| 32 | ADCT ADC Therapeutics SA | Healthcare | 0.4% | $2.7m | 682,529 | – | new |
| 33 | ALMS ALUMIS INC | 0.4% | $2.7m | 665,000 | -14% | reduced | |
| 34 | CABA CABALETTA BIO INC | Healthcare | 0.3% | $1.9m | 808,882 | – | new |
| 35 | IRD OPUS GENETICS INC | 0.3% | $1.8m | 1,100,000 | -10% | reduced | |
| 36 | ZYME ZYMEWORKS INC | Healthcare | 0.2% | $1.7m | 100,000 | -52% | reduced |
| 37 | SYRE SPYRE THERAPEUTICS INC | 0.2% | $1.1m | 65,000 | – | new | |
| 38 | RIGL RIGEL PHARMACEUTICALS | 0.2% | $1.1m | 37,787 | – | new | |
| 39 | ALPHA COGNITION INC | 0.1% | $749.6k | 115,142 | – | new | |
| 40 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.1% | $478.0k | 316,550 | -84% | reduced |
| 41 | PEPG PEPGEN INC | Healthcare | 0.0% | $346.5k | 75,000 | -69% | reduced |
| 42 | IBIO IBIO INC | 0.0% | $310.4k | 375,000 | 0% | held | |
| 43 | ADGM ADAGIO MED HLDGS INC | 0.0% | $214.5k | 110,571 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.